Prosensa Holding

Prosensa Holding B.V. develops therapeutics on the basis of RNA modulation, thereby intervening in an intermediate step in protein biosynthesis.

The company’s lead program is in Duchenne Muscular Dystrophy (DMD), a genetic disorder that blocks the synthesis of an important protein. DMD leads to progressive paralysis and eventually to death. No treatment exists today.

Portfolio: MedSciences Capital B.V. and MedSciences Capital II B.V.

Current stage: NDA submitted. Acquired by Biomarin.